Proactive Investors reported, "Noxopharm welcomes prestigious scientific journal reporting success of Veyonda® as booster of chemotherapy in late-stage cancer patients"
Read more here.
TrialSiteNews reported, "Noxopharm Files Septic Shock Treatment Patent for Veyonda®"
SBS online reported, "Hope for men with advanced prostate cancer after Australian treatment trials".
THE WALL STREET JOURNAL reported, "Noxopharm Files Septic Shock Treatment Patent for Veyonda(R)"
American Pharmaceutical Review presented, "Noxopharm Files Septic Shock Treatment Patent for Veyonda®"
proactive reported, "Noxopharm files patent for Veyonda® as treatment for septic shock."
Noxopharm patent to protect use of drug candidate beyond cancer into septic shock.
Australian digital pharmaceutical news site, Health Industry Hub reported, "Noxopharm and BMS immuno-oncology trial proceeds to patient recruitment"
In its conference data report for the ASCO Genitourinary Cancers Symposium, BioWorld reported on Noxopharm.
Bloomberg Business reported, “Noxopharm Shares Major Cancer Survival Benefit at ASCO Global Conference”.
AddressLevel 4, 828 Pacific Highway Gordon. 2072 NSW AUSTRALIA
PO Box 292, Gordon
2072 NSW AUSTRALIA
50 608 966 123
Join our mailing list to receive the latest information from Noxopharm Limited